TY - JOUR
T1 - Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers
T2 - ASCO guideline update
AU - Loprinzi, Charles L.
AU - Lacchetti, Christina
AU - Bleeker, Jonathan
AU - Cavaletti, Guido
AU - Chauhan, Cynthia
AU - Hertz, Daniel L.
AU - Kelley, Mark R.
AU - Lavino, Antoinette
AU - Lustberg, Maryam B.
AU - Paice, Judith A.
AU - Schneider, Bryan P.
AU - Lavoie Smith, Ellen M.
AU - Smith, Mary Lou
AU - Smith, Thomas J.
AU - Wagner-Johnston, Nina
AU - Hershman, Dawn L.
N1 - Publisher Copyright:
© 2020 by American Society of Clinical Oncology.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - PURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN in addition to 14 primary trials related to treatment of established CIPN, are included in this update. RECOMMENDATIONS The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-L-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited.
AB - PURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN in addition to 14 primary trials related to treatment of established CIPN, are included in this update. RECOMMENDATIONS The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-L-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited.
UR - http://www.scopus.com/inward/record.url?scp=85090313119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090313119&partnerID=8YFLogxK
U2 - 10.1200/JCO.20.01399
DO - 10.1200/JCO.20.01399
M3 - Article
C2 - 32663120
AN - SCOPUS:85090313119
SN - 0732-183X
VL - 38
SP - 3325
EP - 3348
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 28
ER -